Pharmacology Case Studies: MDD, Neuropathy, Insomnia & ADHD
This paper presents four pharmacology case studies examining distinct clinical scenarios. The first addresses a patient with Major Depressive Disorder and coexisting anxiety, recommending sertraline and nicotine replacement therapy. The second covers diabetic peripheral neuropathy, focusing on pregabalin for pain management alongside optimized diabetes care. The third explores zolpidem pharmacokinetics, dosing adjustments for elderly patients, and antidepressant options for co-occurring depression and insomnia. The fourth examines ADHD diagnosis and treatment in both a child and a parent, contrasting stimulant and non-stimulant pharmacological approaches. Each scenario includes diagnosis, medication orders, monitoring parameters, and patient education considerations grounded in current clinical guidelines.
- Scenario 1: Major Depressive Disorder with Anxiety and Nicotine Dependence: Sertraline and nicotine patch for MDD and smoking
- Scenario 2: Diabetic Peripheral Neuropathy Management: Pregabalin and glycemic control for DPN
- Scenario 3: Zolpidem Pharmacokinetics and Insomnia Treatment: Zolpidem half-life, elderly dosing, and antidepressants for insomnia
- Scenario 4: ADHD Diagnosis and Treatment Across Age Groups: Methylphenidate for child, atomoxetine for adult ADHD
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Each case study follows a consistent clinical structure — diagnosis, medication orders, monitoring, and patient education — making it easy to evaluate pharmacological reasoning across different conditions.
- Medication orders include all essential prescribing details (route, frequency, dispensed quantity, refills, titration guidance), reflecting real-world clinical documentation practice.
- The paper integrates current clinical practice guidelines and peer-reviewed references for every scenario, grounding each recommendation in evidence-based medicine.
Key academic technique demonstrated
The paper demonstrates applied pharmacological reasoning — moving from a working diagnosis to a specific, justified treatment plan. Rather than simply naming a medication, the author specifies starting doses, titration schedules, monitoring parameters, and patient education points, showing how pharmacokinetic and patient-specific factors (age, comorbidities, polypharmacy) shape clinical decision-making.
Structure breakdown
The paper is organized into four self-contained clinical scenarios, each functioning as a mini case study. Within each scenario, content flows from diagnosis to treatment selection, prescribing details, monitoring requirements, and relevant education or safety considerations. References are provided per scenario rather than in a single list, reinforcing the evidence base for each individual clinical decision.
Scenario 1: Major Depressive Disorder with Anxiety and Nicotine Dependence
Diagnosis: The patient is likely experiencing Major Depressive Disorder (MDD) with coexisting anxiety, given her symptoms of persistent sadness, anxiety, and an "empty mood" (Walter et al., 2023). Her increased smoking indicates a need to address both her mood disorder and nicotine dependence concurrently.
Antidepressant: First-line treatment involves initiating a selective serotonin reuptake inhibitor (SSRI), which can treat both depression and anxiety.
Medication: Sertraline 50 mg PO daily
Smoking Cessation: Smoking cessation is recommended to address both health concerns and to improve mental health outcomes (White et al., 2023).
Medication: Nicotine replacement therapy (NRT) via transdermal patch — Nicotine transdermal patch 21 mg/24 hours
Sørensen, A., Juhl Jørgensen, K., & Munkholm, K. (2022). Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review. Therapeutic Advances in Psychopharmacology, 12, 20451253211067656.
Walter, H. J., Abright, A. R., Bukstein, O. G., Diamond, J., Keable, H., Ripperger-Suhler, J., & Rockhill, C. (2023). Clinical practice guideline for the assessment and treatment of children and adolescents with major and persistent depressive disorders. Journal of the American Academy of Child & Adolescent Psychiatry, 62(5), 479–502.
White, S. A., Stone, E., Murphy, K. A., Daumit, G. L., & McGinty, E. E. (2023). Smoking cessation medication prescribing for smokers with and without mental illness. Psychiatric Services, 74(4), 332–340.
Scenario 2: Diabetic Peripheral Neuropathy Management
Diagnosis: Based on the patient's symptoms of pain, numbness, tingling, and balance issues, the working diagnosis is Diabetic Peripheral Neuropathy (DPN), a condition commonly associated with diabetes (American Diabetes Association, 2022).
Neuropathic Pain Management:
Medication: Pregabalin (Lyrica) 75 mg PO BID (Khdour, 2020)
Optimize Diabetes Management:
Statin Therapy:
American Diabetes Association. (2022). Standards of medical care in diabetes — 2022 abridged for primary care providers. Clinical Diabetes, 40(1), 10–38.
Khdour, M. R. (2020). Treatment of diabetic peripheral neuropathy: a review. Journal of Pharmacy and Pharmacology, 72(7), 863–872.
Yildiz, M., Esenboşa, K., & Oktay, A. A. (2020). Hypertension and diabetes mellitus: highlights of a complex relationship. Current Opinion in Cardiology, 35(4), 397–404.
Always verify citation format against your institution’s current style guide requirements.